HTTIF (HighTide Therapeutics) Days Payable: 0.00 (As of Dec. 2025)


HTTIF HighTide Therapeutics Inc HTTIF
14 GF Score
Price $0.35
! 3 Warning Signs
View Full Analysis

What is HighTide Therapeutics Days Payable?

HighTide Therapeutics HTTIF 14 Days Payable is 0.00 as of Dec. 2025. GuruFocus rates HTTIF with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 708 Biotechnology companies, HighTide Therapeutics ranks worse than 141242.8% on this metric.

HighTide Therapeutics's average Accounts Payable for the six months ended in Dec. 2025 was $7.43 Mil. HighTide Therapeutics's Cost of Goods Sold for the six months ended in Dec. 2025 was $0.00 Mil.

The historical rank and industry rank for HighTide Therapeutics's Days Payable or its related term are showing as below:

HTTIF's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.56
* Ranked among companies with meaningful Days Payable only.

HighTide Therapeutics's Days Payable stayed the same from Dec. 2024 (0.00) to Dec. 2025 (0.00).

HighTide Therapeutics Days Payable Historical Data

* Premium members only.

The historical data trend for HighTide Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HighTide Therapeutics Days Payable Chart

HighTide Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Days Payable
0.00 0.00 0.00 0.00 0.00

HighTide Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Days Payable Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

HTTIF vs VRTX, REGN, ALNY: Days Payable Comparison

For the Biotechnology subindustry, HighTide Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HighTide Therapeutics Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where HighTide Therapeutics's Days Payable falls into.


HTTIF
14GF Score
HighTide Therapeutics Inc HTTIF
Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HighTide Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

HighTide Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

Days Payable (A: Dec. 2025 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2024 ) + Accounts Payable (A: Dec. 2025 )) / count ) / Cost of Goods Sold (A: Dec. 2025 )*Days in Period
=( (7.07 + 7.225) / 2 ) / 0*365
=7.1475 / 0*365
=N/A

HighTide Therapeutics's Days Payable for the quarter that ended in Dec. 2025 is calculated as:

Days Payable (Q: Dec. 2025 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Jun. 2025 ) + Accounts Payable (Q: Dec. 2025 )) / count ) / Cost of Goods Sold (Q: Dec. 2025 )*Days in Period
=( (7.638 + 7.225) / 2 ) / 0*365 / 2
=7.4315 / 0*365 / 2
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 0.00 mean?
HighTide Therapeutics (HTTIF) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on HighTide Therapeutics and its competitors. According to the industry distribution chart, HighTide Therapeutics ranks #999999 out of 708 companies in the Biotechnology industry.
Is HighTide Therapeutics' Days Payable too high?
HighTide Therapeutics' current Days Payable is 0.00. Based on the distribution chart, HighTide Therapeutics ranks #999999 out of 708 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, HighTide Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does HighTide Therapeutics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HighTide Therapeutics ranks #999999 out of 708 companies for Days Payable. This places HighTide Therapeutics in the lower half of its industry. The industry median Days Payable is 113.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on HighTide Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HighTide Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HighTide Therapeutics stock overvalued right now?
HighTide Therapeutics (HTTIF) has a current Days Payable of 0.00. The current Days Payable is 0.00. HighTide Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For HighTide Therapeutics (HTTIF), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HighTide Therapeutics Business Description

Other Exchanges 02511:Hong Kong
Address Fubao Street, 9th to 10th Floor, Building D, Shenfang Park, Futian District, Shenzhen-Hong Kong Science and, Technology Innovation Cooperation Zone, Guangdong, Shenzhen, CHN, 518112
HighTide Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of first-in-class multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases and related metabolic disorders. The company is developing a pipeline of proprietary drug candidates targeting indications including type 2 diabetes mellitus, chronic kidney disease, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and primary sclerosing cholangitis (PSC). Its core product candidate, HTD1801 (berberine ursodeoxycholate), is an orally delivered first-in-class anti-inflammatory metabolic modulator designed to target dual pathways involving AMPK activation and NLRP3 inflammasome inhibition.
14GF Score

Get the complete analysis for HTTIF

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.35
Price